LivaNova PLC (LIVN)
LivaNova (LIVN) Q2 Earnings and Revenues Beat Estimates
LivaNova (LIVN) came out with quarterly earnings of $1.05 per share, beating the Zacks Consensus Estimate of $0.84 per share. This compares to earnings of $0.93 per share a year ago.
LivaNova: The Sell-Off Is Excessive Here
LivaNova offers strong medtech upside with market-leading positions in cardiac surgery and neuromodulation, but lacks a dividend yield. Recent results show double-digit organic growth, margin expansion, and a positive sales trajectory, especially in Cardiopulmonary. Valuation is attractive: at a discounted 17x P/E, I see 20%+ annual upside and limited downside risk at current prices.
LivaNova (LIVN) Q1 Earnings and Revenues Surpass Estimates
LivaNova (LIVN) came out with quarterly earnings of $0.88 per share, beating the Zacks Consensus Estimate of $0.75 per share. This compares to earnings of $0.73 per share a year ago.
LivaNova (LIVN) Tops Q4 Earnings Estimates
LivaNova (LIVN) came out with quarterly earnings of $0.81 per share, beating the Zacks Consensus Estimate of $0.80 per share. This compares to earnings of $0.87 per share a year ago.
Wall Street Analysts Predict a 37.2% Upside in LivaNova (LIVN): Here's What You Should Know
The mean of analysts' price targets for LivaNova (LIVN) points to a 37.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
LivaNova's OSPREY Sleep Apnea Trail on aura6000 Meets Primary Endpoint
LIVN's aura6000 significantly increases responder rates. The device also reduces AHI and ODI levels.
LivaNova (LIVN) Upgraded to Strong Buy: What Does It Mean for the Stock?
LivaNova (LIVN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
How Much Upside is Left in LivaNova (LIVN)? Wall Street Analysts Think 38.2%
The consensus price target hints at a 38.2% upside potential for LivaNova (LIVN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
LivaNova PLC (LIVN) Q3 2024 Earnings Call Transcript
LivaNova PLC (NASDAQ:LIVN ) Q3 2024 Earnings Conference Call October 30, 2024 8:00 AM ET Company Participants Matthew Dodds - Senior Vice President-Corporate Development & IT Vladimir Makatsaria - Chief Executive Officer Ahmet Tezel - Chief Innovation Officer Alex Shvartsburg - Chief Financial Officer Stephanie Bolton - President, Global Epilepsy Conference Call Participants David Roman - Goldman Sachs Rick Wise - Stifel David Rescott - Baird Michael Pollack - Wolfe Research Adam Maeder - Piper Sandler Anthony Petrone - Mizuho Mike Matson - Needham & Company Matt Miksic - Barclays Operator Good day, ladies and gentlemen, and welcome to the LivaNova PLC Third Quarter 2024 Earnings Conference Call. My name is Lydia, and I'll be your operator today.
LivaNova (LIVN) Tops Q3 Earnings and Revenue Estimates
LivaNova (LIVN) came out with quarterly earnings of $0.90 per share, beating the Zacks Consensus Estimate of $0.71 per share. This compares to earnings of $0.73 per share a year ago.
LivaNova: Economics Should Start Making Sustained Improvements
LivaNova's Essenz product drives revenue growth, with successful rollout and premium pricing boosting guidance despite tough comparisons into the end of the year. Neuromodulation revenues, particularly from epilepsy treatments, show consistent growth, with underpenetrated markets and strong economics supporting secular growth. Discontinuation of the ANTHEM trial and nearing end of the DTD trial is setting up margins for sustained improvements together with operating leverage on growth.
LivaNova's New Strategy Could Unlock Revenue, Profit Gains, Analyst Predicts
Shares of LivaNova Plc LIVN Tuesday climbed along with several other big stocks.
